

# METHODS FOR THE EARLY DIAGNOSIS OF OVARIAN CANCER

5

## Cross-Reference to Related Applications

This is a continuation-in-part application which claims the benefit of priority under 35 USC §120 of USSN 09/861,966, filed May 21, 2001, which is a divisional application of US Pat. No. 6,268,165, which claims the benefit of priority under 35 USC §120 of USSN 09/039,211, filed March 14, 1998, which claims benefit of provisional patent application USSN 60/041,404, filed March 19, 1997, now abandoned.

15

## BACKGROUND OF THE INVENTION

### Field of the Invention

Generally, the present invention relates to the fields of molecular biology and medicine. More specifically, the present invention

invention is in the field of cancer research, especially ovarian cancer diagnosis.

## 5 Background of the Invention

In order for malignant cells to grow, spread or metastasize, they must have the capacity to invade local host tissue, dissociate or shed from the primary tumor, enter and survive in the bloodstream, implant by invasion into the surface of the target organ and establish an environment conducive for new colony growth (including the induction of angiogenic and growth factors). During this progression, natural tissue barriers such as basement membranes and connective tissue have to be degraded. These barriers include collagen, laminin, fibronectin, proteoglycans and extracellular matrix glycoproteins. Degradation of these natural barriers, both those surrounding the primary tumor and at the sites of metastatic invasion, is believed to be brought about by the action of a matrix of extracellular proteases.

Proteases have been classified into four families: serine proteases, metallo-proteases, aspartic proteases and cysteine

proteases. Many proteases have been shown to be involved in human disease processes and these enzymes are targets for the development of inhibitors as new therapeutic agents. Certain individual proteases are induced and overexpressed in a diverse group of cancers, and as such, are potential candidates for markers of early diagnosis and targets for possible therapeutic intervention. A group of examples are shown in Table 1.

**TABLE 1**

Known proteases expressed in various cancers

|                     | Gastric                                       | Brain                                     | Breast  | Ovarian                    |
|---------------------|---|---|---|----------------------------|
| Serine Proteases:   | uPA<br>PAI-1                                  | uPA<br>PAI-1<br>tPA                       | NES-1<br>uPA                                    | NES-1<br>uPA<br>PAI-2      |
| Cysteine Proteases: | Cathepsin B<br>Cathepsin L                    | Cathepsin L                               | Cathepsin B<br>Cathepsin L                      | Cathepsin B<br>Cathepsin L |
| Metallo-proteases:  | Matrilysin*<br>Collagenase*<br>Stromelysin-1* | Matrilysin<br>Stromelysin<br>Gelatinase B | Stromelysin-3<br>MMP-8<br>MMP-9<br>Gelatinase A | MMP-2                      |

uPA, Urokinase-type plasminogen activator; tPA, Tissue-type plasminogen activator; PAI-I, Plasminogen activator 0 inhibitors; PAI-2, Plasminogen activator inhibitors; NES-1, Normal epithelial cell-specific-1; MMP, Matrix P metallo-protease. \*Overexpressed in gastrointestinal ulcers.

There is a good body of evidence supporting the downregulation or inhibition of individual proteases and the reduction in invasive capacity or malignancy. In work by Clark *et al.*, inhibition of *in vitro* growth of human small cell lung cancer was demonstrated using a general serine protease inhibitor. More recently, Torres-Rosedo *et al.*, [*Proc. Natl. Acad. Sci. USA.* 90, 7181-7185 (1993)] demonstrated an inhibition of hepatoma tumor cell growth using specific antisense inhibitors for the serine protease hepsin gene. Metastatic potential of melanoma cells has also been shown to be reduced in a mouse model using a synthetic inhibitor (batimastat) of metallo-proteases. Powell *et al.* [*Cancer Research*, 53, 417-422 (1993)] presented evidence to confirm that the expression of extracellular proteases in a non-metastatic prostate cancer cell line enhances their malignant progression. Specifically, enhanced metastasis was demonstrated after introducing and expressing the PUMP-1 metallo-protease gene. There is also a body of data to support the notion that expression of cell surface proteases on relatively non-metastatic cell types increases the invasive potential of such cells.

To date, ovarian cancer remains the number one killer of women with gynecologic malignant hyperplasia. Approximately 75% of women diagnosed with such cancers are already at an advanced stage (III and IV) of the disease at their initial diagnosis. During the  
5 past 20 years, neither diagnosis nor five-year survival rates have greatly improved for these patients. This is substantially due to the high percentage of high-stage initial detection of the disease. Therefore, the challenge remains to develop new markers that improve early diagnosis and thereby reduce the percentage of high-  
10 stage initial diagnoses. The ability to disengage from one tissue and re-engage the surface of another tissue is what provides for the morbidity and mortality associated with this disease. Therefore, extracellular proteases may be good candidates for markers of malignant ovarian hyperplasia.

15 Thus, the prior art is deficient in a tumor marker useful as an indicator of early disease, particularly for ovarian cancers. The present invention fulfills this long-standing need and desire in the art.

## SUMMARY OF THE INVENTION

This invention allows for the detection of cancer, especially ovarian cancer, by screening for hepsin mRNA in tissue, which is indicative of the hepsin protease, which is shown herein to be specifically associated with the surface of 80 percent of ovarian and other tumors. Proteases are considered to be an integral part of tumor growth and metastasis, and therefore, markers indicative of their presence or absence are useful for the diagnosis of cancer. Furthermore, the present invention is useful for treatment (*i.e.*, by inhibiting hepsin or expression of hepsin), for targeted therapy, for vaccination, etc.

In one embodiment of the present invention, there is provided a method for detecting malignant hyperplasia in a biological sample by detecting hepsin mRNA in the sample. The presence of the hepsin mRNA in the sample is indicative of the presence of malignant hyperplasia, and the absence of the hepsin mRNA in the sample is indicative of the absence of malignant hyperplasia.

In another embodiment of the present invention, there

are provided methods of inhibiting expression of hepsin in a cell by introducing into a cell a vector encoding an antisense hepsin mRNA or an antibody that binds the hepsin protein.

In yet another embodiment of the present invention,  
5 there is provided a method of targeted therapy to an individual, comprising the step of administering a compound to an individual, wherein the compound has a targeting moiety and a therapeutic moiety, wherein the targeting moiety is specific for hepsin.

In still yet another embodiment of the present invention,  
10 there are provided methods of vaccinating an individual against hepsin or produce immune-activated cells directed toward hepsin by inoculating an individual with a hepsin protein or fragment thereof, wherein the hepsin protein or fragment thereof lack hepsin protease activity.

15 In still another embodiment of the present invention, there are provided compositions comprising immunogenic fragments of hepsin protein or an oligonucleotide having a sequence complementary to SEQ ID No. 188. Also embodied is a method of treating a neoplastic state in an individual in need of such treatment  
20 with an effective dose of the above-described oligonucleotide.

09919048-073001  
100E20-8406T660

In another embodiment of the present invention, there is provided a method of screening for compounds that inhibit hepsin activity, comprising the steps of contacting a sample with a compound, wherein the sample comprises hepsin protein; and  
5 assaying for hepsin protease activity. A decrease in the hepsin protease activity in the presence of the compound relative to hepsin protease activity in the absence of the compound is indicative of a compound that inhibits hepsin activity.

Other and further aspects, features, and advantages of  
10 the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.

## 15 BRIEF DESCRIPTION OF THE DRAWINGS

The appended drawings have been included herein so that the above-recited features, advantages and objects of the invention will become clear and can be understood in detail. These  
20 drawings form a part of the specification. It is to be noted, however,



that the appended drawings illustrate preferred embodiments of the invention and should not be considered to limit the scope of the invention.

**Figure 1** shows agarose gel comparison of PCR products derived from normal and carcinoma cDNA.

**Figure 2** shows Northern blot analysis of ovarian tumors using hepsin, SCCE, PUMP-1, TADG-14 and  $\beta$ -tubulin probes.

**Figure 3** shows amplification with serine protease redundant primers: histidine sense (S1) with aspartic acid antisense (AS1), using normal cDNA (Lane 1) and tumor cDNA (Lane 2); and histidine sense (S1) with serine antisense (AS2), using normal cDNA (Lane 3) and tumor cDNA (Lane 4).

**Figure 4** shows amplification with cysteine protease redundant primers. Normal (Lane 1), low malignant potential (Lane 2), serious carcinoma (Lane 3), mucinous carcinoma (Lane 4), and clear cell carcinoma (Lane 5).

**Figure 5** shows amplification with metallo-protease redundant primers. Normal (Lane 1), low malignant potential (Lane 2), serious carcinoma (Lane 3), mucinous carcinoma (Lane 4), and clear cell carcinoma (Lane 5).

Ins B6  
5  
Figure 6 shows amplification with specific primers directed towards the serine protease, hepsin. Expression in normal (Lanes 1-3), low malignant potential tumors (Lanes 4-8), and ovarian carcinomas (Lanes 9-12).

Ins B7  
10  
Figure 7 shows hepsin expression levels in normal, low malignant potential tumors, and ovarian carcinomas. S=serious, M=mucinous, LMP=low malignant potential.

Ins B8  
15  
Figure 8 shows serine protease stratum corneum chymotrypsin enzyme (SCCE) expression in normal, low malignant potential tumors, and ovarian carcinomas.

Ins B9  
20  
Figure 9 shows metallo-protease PUMP-1 (MMP-7) gene expression in normal (lanes 1-2) and ovarian carcinomas tissue (Lanes 3-10).

Ins B9  
25  
Figure 10A shows Northern blot analysis of hepsin expression in normal ovary and ovarian carcinomas. Lane 1, normal ovary (case 10); lane 2, serous carcinoma (case 35); lane 3, mucinous carcinoma (case 48); lane 4, endometrioid carcinoma (case 51); and lane 5, clear cell carcinoma (case 54). In cases 35, 51 and 54, more than a 10-fold increase in the hepsin 1.8 kb transcript abundance was observed. Figure 10B shows Northern blot analysis of hepsin

Ins  
B9

in normal human fetal. **Figure 10C** shows Northern blot analysis of hepsin in adult tissues. Significant overexpression of the hepsin transcript is noted in both fetal liver and fetal kidney. Notably, hepsin overexpression is not observed in normal adult tissue. Slight  
5 expression above the background level is observed in the adult prostate.

Ins  
B10

**Figure 11A** shows hepsin expression in normal (N), mucinous (M) and serous (S) low malignant potential (LMP) tumors and carcinomas (CA).  $\beta$ -tubulin was used as an internal control. **Figure 11B** shows the ratio of hepsin: $\beta$ -tubulin expression in normal ovary, LMP tumor, and ovarian carcinoma. Hepsin mRNA expression levels were significantly elevated in LMP tumors, ( $p < 0.005$ ) and carcinomas ( $p < 0.0001$ ) compared to levels in normal ovary. All 10 cases of normal ovaries showed a relatively low level  
15 of hepsin mRNA expression.

**Figure 12A** shows northern blot analysis of mRNA expression of the SCCE gene in fetal tissue. **Figure 12B** shows northern blot analysis of mRNA expression of the SCCE gene in ovarian tissue.

**Figure 13A** shows a comparison of quantitative PCR of SCCE cDNA from normal ovary and ovarian carcinomas. **Figure 13B** shows a bar graph comparing the ratio of SCCE to  $\beta$ -tubulin in 10 normal and 44 ovarian carcinoma tissues.

**Figure 14** shows a comparison by quantitative PCR of normal and ovarian carcinoma expression of mRNA for protease M.

**Figure 15** shows the TADG-12 catalytic domain including an insert near the His 5'-end.

**Figure 16A** shows northern blot analysis comparing TADG-14 expression in normal and ovarian carcinoma tissues. **Figure 16B** shows preliminary quantitative PCR amplification of normal and carcinoma cDNAs using specific primers for TADG-14.

**Figure 17A** shows northern blot analysis of the PUMP-1 gene in human fetal tissue. **Figure 17B** shows northern blot analysis of the PUMP-1 gene in normal ovary and ovarian carcinomas.

**Figure 18A** shows a comparison of PUMP-1 expression in normal and carcinoma tissues using quantitative PCR with an internal  $\beta$ -tubulin control. **Figure 18B** shows the ratio of mRNA

expression of PUMP-1 compared to the internal control  $\beta$ -tubulin in 10 normal and 44 ovarian carcinomas.

**Figure 19** shows a comparison of PCR amplified products for the hepsin, SCCE, protease M, PUMP-1 and Cathepsin L genes.

**Figure 20** shows CD8<sup>+</sup> CTL recognition of hepsin 170-178 peptide in a 5 hour <sup>51</sup>Cr release assay. Targets were LCL loaded with hepsin 170-178 (closed circles) and control LCL (open circles).

**Figure 21** shows CD8<sup>+</sup> CTL recognition of hepsin 172-180 peptide in a 5 hr <sup>51</sup>Cr release assay. Targets were LCL loaded with hepsin 172-180 (closed circles) and control LCL (open circles).

## DETAILED DESCRIPTION OF THE INVENTION

This invention identifies hepsin protease as a marker for ovarian tumor cells. In various combinations with other proteases, hepsin expression is characteristic of individual tumor types. Such information can provide the basis for diagnostic tests (assays or immunohistochemistry) and prognostic evaluation (depending on the

display pattern). Long-term treatment of tumor growth, invasion and metastasis has not succeeded with existing chemotherapeutic agents. Most tumors become resistant to drugs after multiple cycles of chemotherapy. The present invention identifies hepsin as a new  
5 therapeutic intervention target utilizing either antibodies directed at the protease, antisense vehicles for downregulation or protease inhibitors both from established inhibition data and/or for the design of new drugs.

A primary object of the present invention is a method for  
10 detecting the presence of malignant hyperplasia in a tissue sample. The cancer is detected by analyzing a biological sample for the presence of markers to proteases that are specific indicators of certain types of cancer cells. This object may be accomplished by isolating mRNA from a sample or by detection of proteins by  
15 polyclonal or preferably monoclonal antibodies. When using mRNA detection, the method may be carried out by converting the isolated mRNA to cDNA according to standard methods; treating the converted cDNA with amplification reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate  
20 mixture of nucleic acid primers selected from the list in Table 2;

reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of malignant hyperplasia markers in the sample. The analyzing step may be accomplished using Northern Blot analysis to  
5 detect the presence of malignant hyperplasia markers in the amplification product. Northern Blot analysis is known in the art. The analysis step may be further accomplished by quantitatively detecting the presence of malignant hyperplasia marker in the amplification products, and comparing the quantity of marker  
10 detected against a panel of expected values for known presence or absence in normal and malignant tissue derived using similar primers.

The present invention also provides various nucleic acid sequences that are useful in the methods disclosed herein. These  
15 nucleic acid sequences are listed in Table 2. It is anticipated that these nucleic acid sequences be used in mixtures to accomplish the utility of this invention. Features of such mixtures include: SEQ ID No. 1 with SEQ ID No. 2; SEQ ID No. 1 with SEQ ID No. 3; SEQ ID No. 4 with SEQ ID No. 5; SEQ ID No. 6 with SEQ ID No. 7; SEQ ID No. 8 with  
20 SEQ ID No. 9; and SEQ ID No. 10 with SEQ ID No. 11. The skilled

artisan may be able to develop other nucleic acid sequences and mixtures thereof to accomplish the benefit of this invention, but it is advantageous to have the sequences listed in Table 2 available without undue experimentation.

5           The present invention provides a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating mRNA from the sample; and detecting hepsin mRNA in the sample. The presence of the hepsin mRNA in the sample is indicative of the presence of malignant hyperplasia, wherein the  
10   absense of the hepsin mRNA in the sample is indicative of the absence of malignant hyperplasia. This method may further comprise the step of comparing the hepsin mRNA to reference information, wherein the comparison provides a diagnosis and/or determines a treatment of the malignant hyperplasia. A typical  
15   means of detection of hepsin mRNA is by PCR amplification, which, preferably, uses primers shown in SEQ ID No. 8 and SEQ ID No. 9. Representative biological samples are blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells.

20           The present invention is further directed toward a



method of inhibiting expression of hepsin in a cell, comprising the step of introducing into a cell a vector comprises a hepsin gene operably linked in opposite orientation to elements necessary for expression, wherein expression of the vector produces hepsin antisense mRNA in the cell. The hepsin antisense mRNA hybridizes to endogenous hepsin mRNA, thereby inhibiting expression of hepsin in the cell.

The present invention is still further directed toward a method of inhibiting a hepsin protein in a cell, comprising the step of introducing an antibody into a cell, wherein the antibody is specific for a hepsin protein or a fragment thereof. Binding of the antibody to hepsin inhibits the hepsin protein. Preferably, the hepsin fragment is a 9-residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 and 154.

The present invention is also directed toward a method of targeted therapy to an individual, comprising the step of administering a compound to an individual, wherein the compound has a targeting moiety and a therapeutic moiety, and wherein the targeting moiety is specific for hepsin. Preferably, the targeting

moiety is an antibody specific for hepsin or a ligand or ligand binding domain that binds hepsin. Likewise, the therapeutic moiety is preferably a radioisotope, a toxin, a chemotherapeutic agent, an immune stimulant or cytotoxic agent. Generally, the individual  
5 suffers from a disease such as ovarian cancer, lung cancer, prostate cancer, colon cancer or another cancer in which hepsin is overexpressed.

The present invention is additionally directed toward a method of vaccinating an individual against hepsin, comprising the  
10 steps of inoculating an individual with a hepsin protein or fragment thereof, wherein the hepsin protein or fragment thereof lack hepsin protease activity. Inoculation with the hepsin protein, or fragment thereof, elicits an immune response in the individual, thereby vaccinating the individual against hepsin. Generally, this method is  
15 applicable when the individual has cancer, is suspected of having cancer or is at risk of getting cancer. Sequences of preferred hepsin proteins or fragment thereof are shown in SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 and 154.

The present invention is yet directed toward a method of  
20 producing immune-activated cells directed toward hepsin,

comprising the steps of exposing immune cells to hepsin protein or fragment thereof that lacks hepsin protease activity. Typically, exposure to hepsin protein or fragment thereof activates the immune cells, thereby producing immune-activated cells directed toward hepsin. Generally, the immune-activated cells are B-cells, T-cells and/or dendritic cells. Preferably, the hepsin fragment is a 9-residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 or 154. Oftentimes, the dendritic cells are isolated from an individual prior to exposure and then reintroduced into the individual subsequent to the exposure. Typically, the individual has cancer, is suspected of having cancer or is at risk of getting cancer.

The present invention is further directed toward an immunogenic composition, comprising an immunogenic fragment of hepsin protein and an appropriate adjuvant. Preferably, the fragment is a 9-residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 or 154.

The present invention is further directed toward an

09919048-073001  
FOOEEZD"8406F660

oligonucleotide having a sequence complementary to SEQ ID No.188  
or a fragment thereof. The present invention further provides a  
composition comprising the above-described oligonucleotide and a  
physiologically acceptable carrier, and a method of treating a  
5 neoplastic state in an individual in need of such treatment,  
comprising the step of administering to the individual an effective  
dose of the above-described oligonucleotide. Typically, the  
neoplastic state may be ovarian cancer, breast cancer, lung cancer,  
colon cancer, prostate cancer or another cancer in which hepsin is  
10 overexpressed.

The present invention is still further directed toward a  
method of screening for compounds that inhibit hepsin activity,  
comprising the steps of contacting a sample with a compound,  
wherein the sample comprises hepsin protein; and assaying for  
15 hepsin protease activity. A decrease in the hepsin protease activity  
in the presence of the compound relative to hepsin protease activity  
in the absence of the compound is indicative of a compound that  
inhibits hepsin activity.

It will be apparent to one skilled in the art that various  
20 substitutions and modifications may be made to the invention

disclosed herein without departing from the scope and spirit of the invention.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual" (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins eds. 1985); "Transcription and Translation" (B.D. Hames & S.J. Higgins eds. 1984); "Animal Cell Culture" (R.I. Freshney, ed. 1986); "Immobilized Cells And Enzymes" (IRL Press, 1986); B. Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing herein, the following terms shall have the definitions set out below.

As used herein, the term "cDNA" shall refer to the DNA copy of the mRNA transcript of a gene.

As used herein, the term "PCR" refers to the polymerase chain reaction that is the subject of U.S. Patent Nos. 4,683,195 and 4,683,202 to Mullis, as well as other improvements now known in

the art.

The present invention comprises a vector comprising a DNA sequence which encodes a hepsin protein, wherein said vector is capable of replication in a host, and comprises, in operable linkage: a) an origin of replication; b) a promoter; and c) a DNA sequence coding for said hepsin protein. Preferably, the vector of the present invention contains a portion of the DNA sequence shown in SEQ ID No. 188. Vectors may be used to amplify and/or express nucleic acid encoding a hepsin protein, a fragment of hepsin protein, or an antisense hepsin mRNA.

An expression vector is a replicable construct in which a nucleic acid sequence encoding a polypeptide is operably linked to suitable control sequences capable of effecting expression of the polypeptide in a cell. The need for such control sequences will vary depending upon the cell selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter and/or enhancer, suitable mRNA ribosomal binding sites and sequences which control the termination of transcription and translation. Methods which are well known to those skilled in the art can be used to construct expression vectors containing

appropriate transcriptional and translational control signals. See, for example, techniques described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual* (2nd Ed.), Cold Spring Harbor Press, N.Y. A gene and its transcription control sequences are defined as being "operably linked" if the transcription control sequences effectively control transcription of the gene. Vectors of the invention include, but are not limited to, plasmid vectors and viral vectors. Preferred viral vectors of the invention are those derived from retroviruses, adenovirus, adeno-associated virus, SV40 virus, or herpes viruses.

As used herein, the term "host" is meant to include not only prokaryotes but also eukaryotes such as yeast, plant and animal cells. A recombinant DNA molecule or gene which encodes a human hepsin protein of the present invention can be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Especially preferred is the use of a vector containing coding sequences for the gene which encodes a human hepsin protein of the present invention for purposes of prokaryote transformation. Prokaryotic hosts may include *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. Eukaryotic

hosts include yeasts such as *Pichia pastoris*, mammalian cells and insect cells.

The term "oligonucleotide", as used herein, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors, which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer", as used herein, refers to an oligonucleotide, whether occurring naturally (as in a purified restriction digest) or produced synthetically, and which is capable of initiating synthesis of a strand complementary to a nucleic acid when placed under appropriate conditions, *i.e.*, in the presence of nucleotides and an inducing agent, such as a DNA polymerase, and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, sequence and/or homology of primer and the method used. For example, in diagnostic applications, the oligonucleotide primer typically contains 15-25 or more nucleotides, depending upon the complexity of the target sequence,



although it may contain fewer nucleotides.

The primers herein are selected to be "substantially" complementary to particular target DNA sequences. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment (*i.e.*, containing a restriction site) may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementary with the sequence to hybridize therewith and form the template for synthesis of the extension product.

The probe to which the DNA of the invention hybridizes preferably consists of a sequence of at least 20 consecutive nucleotides, more preferably 40 nucleotides, even more preferably 50 nucleotides, and most preferably 100 nucleotides or more (up to 100%) of the coding sequence of the nucleotides listed in SEQ ID No. 188 or the complement thereof. Such a probe is useful for detecting expression of hepsin in a cell by a method including the steps of (a)

contacting mRNA obtained from the cell with a labeled hepsin hybridization probe; and (b) detecting hybridization of the probe with the mRNA.

As used herein, "substantially pure DNA" means DNA that is not part of a milieu in which the DNA naturally occurs, by virtue of separation (partial or total purification) of some or all of the molecules of that milieu, or by virtue of alteration of sequences that flank the claimed DNA. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (*e.g.*, a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, *e.g.*, a fusion protein. Also included is a recombinant DNA which includes a portion of the nucleotides listed in SEQ ID No. 188 and which encodes an alternative splice variant of hepsin.

The DNA may have at least about 70% sequence identity

to the coding sequence of the nucleotides listed in SEQ ID No. 188,  
preferably at least 75% (*e.g.*, at least 80%); and most preferably at  
least 90%. The identity between two sequences is a direct function  
of the number of matching or identical positions. When a position in  
5 both of the two sequences is occupied by the same monomeric  
subunit, *e.g.*, if a given position is occupied by an adenine in each of  
two DNA molecules, then they are identical at that position. For  
example, if 7 positions in a sequence 10 nucleotides in length are  
identical to the corresponding positions in a second 10-nucleotide  
10 sequence, then the two sequences have 70% sequence identity. The  
length of comparison sequences will generally be at least  
50 nucleotides, preferably at least 60 nucleotides, more preferably  
at least 75 nucleotides, and most preferably 100 nucleotides.  
Sequence identity is typically measured using sequence analysis  
15 software (*e.g.*, Sequence Analysis Software Package of the Genetics  
Computer Group (GCG), University of Wisconsin Biotechnology Center,  
1710 University Avenue, Madison, WI 53705).

Further included in this invention are hepsin proteins  
which are encoded, at least in part, by portions of SEQ ID No. 188,  
20 *e.g.*, products of alternative mRNA splicing or alternative protein

processing events, or in which a section of hepsin sequence has been deleted. The fragment, or the intact hepsin polypeptide, may be covalently linked to another polypeptide, *e.g.*, one which acts as a label, a ligand or a means to increase antigenicity.

5           A substantially pure hepsin protein may be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding a hepsin polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, *e.g.*, column chromatography, such as  
10 immunoaffinity chromatography using an antibody specific for hepsin, polyacrylamide gel electrophoresis, or HPLC analysis. A protein is substantially free of naturally associated components when it is separated from at least some of those contaminants which accompany it in its natural state. Thus, a protein which is chemically  
15 synthesized or produced in a cellular system different from the cell from which it naturally originates will be, by definition, substantially free from its naturally associated components. Accordingly, substantially pure proteins include eukaryotic proteins synthesized in *E. coli*, other prokaryotes, or any other organism in which they do  
20 not naturally occur.

In addition to substantially full-length proteins, the invention also includes fragments (*e.g.*, antigenic fragments) of the hepsin protein. As used herein, "fragment," as applied to a polypeptide, will ordinarily be at least 10 residues, more typically at least 20 residues, and preferably at least 30 (*e.g.*, 50) residues in length, but less than the entire, intact sequence. Fragments of the hepsin protein can be generated by methods known to those skilled in the art, *e.g.*, by enzymatic digestion of naturally occurring or recombinant hepsin protein, by recombinant DNA techniques using an expression vector that encodes a defined fragment of hepsin, or by chemical synthesis. The ability of a candidate fragment to exhibit a characteristic of hepsin (*e.g.*, binding to an antibody specific for hepsin) can be assessed by methods known in the art. Purified hepsin or antigenic fragments of hepsin can be used to generate new antibodies or to test existing antibodies (*e.g.*, as positive controls in a diagnostic assay) by employing standard protocols known to those skilled in the art. Included in this invention is polyclonal antisera generated by using hepsin or a fragment of hepsin as the immunogen in, *e.g.*, rabbits. Standard protocols for monoclonal and polyclonal antibody production known to those skilled in this art are

employed. The monoclonal antibodies generated by this procedure can be screened for the ability to identify recombinant hepsin cDNA clones, and to distinguish them from other cDNA clones.

The invention encompasses not only an intact anti-hepsin monoclonal antibody, but also an immunologically-active antibody fragment, *e.g.*, a Fab or (Fab)<sub>2</sub> fragment; an engineered single chain Fv molecule; or a chimeric molecule, *e.g.*, an antibody which contains the binding specificity of one antibody, *e.g.*, of murine origin, and the remaining portions of another antibody, *e.g.*, of human origin.

In one embodiment, the antibody, or a fragment thereof, may be linked to a toxin or to a detectable label, *e.g.*, a radioactive label, non-radioactive isotopic label, fluorescent label, chemiluminescent label, paramagnetic label, enzyme label, or colorimetric label. Examples of suitable toxins include diphtheria toxin, *Pseudomonas* exotoxin A, ricin, and cholera toxin. Examples of suitable enzyme labels include malate hydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-

phosphate dehydrogenase, glucoamylase, acetylcholinesterase, etc.  
Examples of suitable radioisotopic labels include  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  
 $^{14}\text{C}$ , etc.

Paramagnetic isotopes for purposes of *in vivo* diagnosis  
5 can also be used according to the methods of this invention. There  
are numerous examples of elements that are useful in magnetic  
resonance imaging. For discussions on *in vivo* nuclear magnetic  
resonance imaging, see, for example, Schaefer et al., (1989) *JACC* 14,  
472-480; Shreve et al., (1986) *Magn. Reson. Med.* 3, 336-340; Wolf,  
10 G. L., (1984) *Physiol. Chem. Phys. Med. NMR* 16, 93-95; Wesbey  
et al., (1984) *Physiol. Chem. Phys. Med. NMR* 16, 145-155; Runge et  
al., (1984) *Invest. Radiol.* 19, 408-415. Examples of suitable  
fluorescent labels include a fluorescein label, an isothiocyalate label,  
a rhodamine label, a phycoerythrin label, a phycocyanin label, an  
15 allophycocyanin label, an ophthaldehyde label, a fluorescamine label,  
etc. Examples of chemiluminescent labels include a luminal label, an  
isoluminal label, an aromatic acridinium ester label, an imidazole  
label, an acridinium salt label, an oxalate ester label, a luciferin label,  
a luciferase label, an aequorin label, etc.

Those of ordinary skill in the art will know of other

09919048-073001  
T00E20"8406T660  
suitable labels which may be employed in accordance with the present invention. The binding of these labels to antibodies or fragments thereof can be accomplished using standard techniques commonly known and used by those of ordinary skill in the art.

5 Typical techniques are described by Kennedy et al., (1976) *Clin. Chim. Acta* 70, 1-31; and Schurs et al., (1977) *Clin. Chim. Acta* 81, 1 - 40. Coupling techniques mentioned in the latter are the glutaraldehyde method, the periodate method, the dimaleimide method, the m-maleimidobenzyl-N-hydroxy-succinimide ester  
10 method. All of these methods are incorporated by reference herein.

Also within the invention is a method of detecting hepsin protein in a biological sample, which includes the steps of contacting the sample with the labeled antibody, *e.g.*, radioactively tagged antibody specific for hepsin, and determining whether the antibody  
15 binds to a component of the sample. Antibodies to the hepsin protein can be used in an immunoassay to detect increased levels of hepsin protein expression in tissues suspected of neoplastic transformation. These same uses can be achieved with Northern blot assays and analyses.

20 As described herein, the invention provides a number of



diagnostic advantages and uses. For example, the hepsin protein is useful in diagnosing cancer in different tissues since this protein is highly overexpressed in tumor cells. Antibodies (or antigen-binding fragments thereof) which bind to an epitope specific for hepsin are  
5 useful in a method of detecting hepsin protein in a biological sample for diagnosis of cancerous or neoplastic transformation. This method includes the steps of obtaining a biological sample (*e.g.*, cells, blood, plasma, tissue, etc.) from a patient suspected of having cancer, contacting the sample with a labeled antibody (*e.g.*, radioactively  
10 tagged antibody) specific for hepsin, and detecting the hepsin protein using standard immunoassay techniques such as an ELISA. Antibody binding to the biological sample indicates that the sample contains a component which specifically binds to an epitope within hepsin.

Likewise, a standard Northern blot assay can be used to  
15 ascertain the relative amounts of hepsin mRNA in a cell or tissue obtained from a patient suspected of having cancer, in accordance with conventional Northern hybridization techniques known to those of ordinary skill in the art. This Northern assay uses a hybridization probe, *e.g.*, radiolabelled hepsin cDNA, either containing the full-  
20 length, single stranded DNA having a sequence complementary to

SEQ ID No. 188, or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labeled by any of the many different methods known to those skilled in this art.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion:

### EXAMPLE 1

#### Amplification Of Serine Proteases Using Redundant And Specific Primers

Only cDNA preparations deemed free of genomic DNA were used for gene expression analysis. Redundant primers were prepared for serine proteases, metallo-proteases and cysteine protease. The primers were synthesized to consensus sequences of amino acid surrounding the catalytic triad for serine proteases, *viz.* histidine ... aspartate ... and serine. The sequences of both sense

(histidine & aspartate) and antisense (aspartate and serine)  
redundant primers are shown in Table 2.

T00E20" 8406T660

TABLE 2

| PCR Primers                                     | 5'→3'                                     | SEQ ID |
|---|---|--------|
| No.   |   |        |
| <u>Redundant Primers:</u>                       |   |        |
| 5 Serine Protease (histidine) = S1              | tgggtigtiaicigcigcica(ct)tg               | 1      |
| Serine Protease (aspartic acid) = AS1           | a(ag)ia(ag)igciatitcitticc                | 2      |
| Serine Protease (serine) = AS11                 | a(ag)iggicccici(cg)(ta)(ag)tcicc          | 3      |
| Cysteine Protease - sense                       | ca(ag)ggica(ag)tg(ct)ggi(ta)(cg)itg(ct)tg | 4      |
| Cysteine Protease - antisense                   | taicccicc(ag)tt(ag)caicc(ct)tc            | 5      |
| 10 Metallo Protease - sense                     | cci(ac)gitg(tc)ggi(ga)(ta)icciga          | 6      |
| Metallo Protease - antisense                    | tt(ag)tgiicciai(ct)tc(ag)tg               | 7      |
| <u>Specific Primers:</u>                        |   |        |
| Serine Protease (hepsin) = sense                | tgtcccgatggcgagtgttt                      | 8      |
| Serine Protease (hepsin) = antisense            | cctgttgccatagtactgc                       |        |
| 15 Serine Protease (SCCE) = sense               | agatgaatgagtacaccgtg                      | 10     |
| Serine Protease (SCCE) = antisense              | ccagtaagtccttgtaaacc                      | 11     |
| Serine Protease (Comp B) = sense                | aaggacacgagagctgtat                       | 12     |
| Serine Protease (Comp B) = antisense            | aagtggtagttggaggaagc                      | 13     |
| Serine Protease (Protease M)= sense             | ctgtgatccaccctgactat                      | 20     |
| 20 Serine Protease (Protease M) = antisense     | caggtggatgtatgcacact                      | 21     |
| Serine Protease (TADG12) = sense (Ser10-s)      | gcgcactgtgtttatgagat                      | 22     |
| Serine Protease (TADG12) = antisense (Ser10-as) | ctctttggcttgacttgct                       | 23     |
| Serine Protease (TADG13) = sense                | tgaggacatcattatgcac                       | 24     |
| Serine Protease (TADG13) = antisense            | caagttttccccataattgg                      | 25     |
| 25 Serine Protease (TADG14) = sense             | acagtacgcctgggagacca                      | 26     |
| Serine Protease (TADG14) = antisense            | ctgagacggtgcaattctgg                      | 27     |
| Cysteine Protease (Cath-L) = sense              | attggagagagaaaggctac                      | 14     |
| Cysteine Protease (Cath-L) = antisense          | cttgggattgtacttacagg                      | 15     |
| Metallo Protease (PUMP1) = sense                | cttccaaagtggtcacctac                      | 16     |
| 30 Metallo Protease (PUMP1) = antisense         | ctagactgctaccatccgtc                      | 17     |

## EXAMPLE 2

### Carcinoma Tissue

5                Several protease entities were identified and subcloned  
from PCR amplification of cDNA derived from serous  
cystadenocarcinomas. Therefore, the proteases described herein are  
reflective of surface activities for this type of carcinoma, the most  
common form of ovarian cancer. Applicant also shows PCR  
10            amplification bands of similar base pair size unique to the mucinous  
tumor type and the clear cell type. About 20-25% of ovarian cancers  
are classified as either mucinous, clear cell, or endometrioid.

## EXAMPLE 3

### Ligation, Transformation And Sequencing

To determine the identity of the PCR products, all the  
appropriate bands were ligated into Promega T-vector plasmid and  
20            the ligation product was used to transform JM109 cells (Promega)

grown on selective media. After selection and culturing of individual colonies, plasmid DNA was isolated by means of the WIZARD MINIPREP™ DNA purification system (Promega). Inserts were sequenced using a Prism Ready Reaction Dydeoxy Terminators cycle sequencing kit (Applied Biosystems). Residual dye terminators were removed from the completed sequencing reaction using a CENTRISEP SPIN™ column (Princeton Separation), and samples were loaded into an Applied Biosystems Model 373A DNA sequencing system. The results of subcloning and sequencing for the serine protease primers are summarized in Table 3.

**TABLE 3**

**Serine protease candidates**

|    | <u>Subclone</u> | <u>Primer Set</u> | <u>Gene Candidate</u> |
|----|-----------------|-------------------|-----------------------|
| 5  | 1               | His-Ser           | Hepsin                |
|    | 2               | His-Ser           | SCCE                  |
|    | 3               | His-Ser           | Compliment B          |
|    | 4               | His-Asp           | Cofactor 1            |
|    | 5               | His-Asp           | TADG-12*              |
| 10 | 6               | His-Ser           | TADG-13*              |
|    | 7               | His-Ser           | TADG-14*              |
|    | 8               | His-Ser           | Protease M            |
|    | 9               | His-Ser           | TADG-15*              |

\*indicates novel proteases

**EXAMPLE 4**

**Cloning And Characterization**

Cloning and characterization of new gene candidates was undertaken to expand the panel representative of extracellular proteases specific for ovarian carcinoma subtypes. Sequencing of the

PCR products derived from tumor cDNA confirms the potential candidacy of these genes. The three novel genes all have conserved residues within the catalytic triad sequence consistent with their membership in the serine protease family.

5           Applicant compared the PCR products amplified from normal and carcinoma cDNAs using sense-histidine and antisense-aspartate as well as sense-histidine and antisense-serine. The anticipated PCR products of approximately 200 bp and 500 bp for those pairs of primers were observed (aspartate is approximately  
10 50-70 amino acids downstream from histidine, and serine is about 100-150 amino acids toward the carboxy end from histidine).

Figure 1 shows a comparison of PCR products derived from normal and carcinoma cDNA as shown by staining in an agarose gel. Two distinct bands in Lane 2 were present in the primer pair  
15 sense-His/antisense ASP (AS1) and multiple bands of about 500 bp are noted in the carcinoma lane for the sense-His/antisense-Ser (AS2) primer pairs in Lane 4.



## EXAMPLE 5

### Quantitative PCR

The mRNA overexpression of hepsin was detected and  
5 determined using quantitative PCR. Quantitative PCR was performed  
generally according to the method of Noonan et al. [*Proc. Natl. Acad.  
Sci. USA*, 87:7160-7164 (1990)]. The following oligonucleotide  
primers were used:

hepsin:

10 forward 5'-TGTCCCGATGGCGAGTGTTT-3' (SEQ ID No. 8), and  
reverse 5'-CCTGTTGGCCATAGTACTGC-3' (SEQ ID No. 9);

and  $\beta$ -tubulin:

forward 5'- TGCATTGACAACGAGGC -3' (SEQ ID No. 18), and  
reverse 5'- CTGTCTTGA CATTGTTG -3' (SEQ ID No. 19).

15  $\beta$ -tubulin was utilized as an internal control. The predicted sizes of  
the amplified genes were 282 bp for hepsin and 454 bp for  $\beta$ -  
tubulin. The primer sequences used in this study were designed  
according to the cDNA sequences described by Leytus et al.  
[*Biochemistry*, 27, 1067-1074 (1988)] for hepsin, and Hall et al. [*Mol.*

*Cell. Biol.*, 3, 854-862 (1983)] for  $\beta$ -tubulin. The PCR reaction mixture consisted of cDNA derived from 50 ng of mRNA converted by conventional techniques, 5 pmol of sense and antisense primers for both the hepsin gene and the  $\beta$ -tubulin gene, 200  $\mu$ mol of dNTPs, 5  $\mu$ Ci of  $\alpha$ -<sup>32</sup>PdCTP and 0.25 units of Taq DNA polymerase with reaction buffer (Promega) in a final volume of 25  $\mu$ l. The target sequences were amplified in parallel with the  $\beta$ -tubulin gene. Thirty cycles of PCR were carried out in a Thermal Cycler (Perkin-Elmer Cetus). Each cycle of PCR included 30 sec of denaturation at 95°C, 30 sec of annealing at 63°C and 30 sec of extension at 72°C. The PCR products were separated on 2% agarose gels and the radioactivity of each PCR product was determined by using a PhosphorImager™ (Molecular Dynamics). Student's *t* test was used for comparison of mean values.

Experiments comparing PCR amplification in normal ovary and ovarian carcinoma suggested overexpression and/or alteration in mRNA transcript in tumor tissues. Northern blot analysis of TADG-14 confirms a transcript size of 1.4 kb and data indicate overexpression in ovarian carcinoma (Figure 2). Isolation

and purification using both PCR and a specific 250 bp PCR product to screen positive plaques yielded a 1.2 kb clone of TADG-14. Other proteases were amplified by the same method using the appropriate primers from Table 2.

5

### **EXAMPLE 6**

#### **Tissue Bank**

A tumor tissue bank of fresh frozen tissue of ovarian carcinomas as shown in Table 4 was used for evaluation. Approximately 100 normal ovaries removed for medical reasons other than malignancy were obtained from surgery and were available as controls.

TABLE 4

Ovarian cancer tissue bank

| 5  |                     | <u>Total</u> | <u>Stage I/II</u> | <u>Stage III/IV</u> | <u>No</u> |
|----|---------------------|--------------|-------------------|---------------------|-----------|
|    | <u>Stage</u>        |              |                   |                     |           |
|    | <u>Serous</u>       |              |                   |                     |           |
|    | Malignant           | 166          | 15                | 140                 | 8         |
|    | LMP                 | 16           | 9                 | 7                   | 0         |
| 10 | Benign              | 12           | 0                 | 0                   | 12        |
|    | <u>Mucinous</u>     |              |                   |                     |           |
|    | Malignant           | 26           | 6                 | 14                  | 6         |
|    | LMP                 | 28           | 25                | 3                   | 0         |
|    | Benign              | 3            | 0                 | 0                   | 3         |
| 15 | <u>Endometrioid</u> |              |                   |                     |           |
|    | Malignant           | 38           | 17                | 21                  | 0         |
|    | LMP                 | 2            | 2                 | 0                   | 0         |
|    | Benign              | 0            | 0                 | 0                   | 0         |
|    | <u>Other*</u>       |              |                   |                     |           |
| 20 | Malignant           | 61           | 23                | 29                  | 9         |
|    | LMP                 | 0            | 0                 | 0                   | 0         |
|    | Benign              | 5            | 0                 | 0                   | 5         |

\*Other category includes the following tumor types: Brenner's tumor, thecoma, teratoma, fibrothecoma, fibroma, granulosa cell, clear cell, germ cell, mixed mullerian, stromal, undifferentiated, and dysgerminoma.

From the tumor bank, approximately 100 carcinomas were evaluated encompassing most histological sub-types of ovarian carcinoma, including borderline or low-malignant potential tumors and overt carcinomas. The approach included using mRNA prepared from fresh frozen tissue (both normal and malignant) to compare expression of genes in normal, low malignant potential tumors and overt carcinomas. The cDNA prepared from polyA<sup>+</sup> mRNA was deemed to be genomic DNA-free by checking all preparations with primers that encompassed a known intron-exon splice site using both  $\beta$ -tubulin and p53 primers.

### EXAMPLE 7

#### Northern Blots Analysis

Significant information can be obtained by examining the expression of these candidate genes by Northern blot. Analysis of normal adult multi-tissue blots offers the opportunity to identify normal tissues which may express the protease. Ultimately, if strategies for inhibition of proteases for therapeutic intervention are to be developed, it is essential to appreciate the expression of these

genes in normal tissues.

Significant information is expected from Northern blot analysis of fetal tissue. Genes overexpressed in carcinomas are often highly expressed in organogenesis. As indicated, the hepsin gene  
5 cloned from hepatoma cells and overexpressed in ovarian carcinoma is overtly expressed in fetal liver. Hepsin gene expression was also detected in fetal kidney, and therefore, could be a candidate for expression in renal carcinomas.

Northern panels for examining expression of genes in a  
10 multi-tissue normal adult as well as fetal tissue are commercially available (CLONTECH). Such evaluation tools are not only important to confirm the overexpression of individual transcripts in tumor versus normal tissues, but also provides the opportunity to confirm transcript size, and to determine if alternate splicing or other  
15 transcript alteration may occur in ovarian carcinoma.

Northern blot analysis was performed as follows: 10 µg of mRNA was loaded onto a 1% formaldehyde-agarose gel, electrophoresed and blotted onto a HyBond-N<sup>+</sup>™ nylon membrane (Amersham). <sup>32</sup>P-labeled cDNA probes were made using Prime-a-  
20 Gene Labeling System™ (Promega). The PCR products amplified by

specific primers were used as probes. Blots were prehybridized for 30 min and then hybridized for 60 min at 68°C with <sup>32</sup>P-labeled cDNA probe in ExpressHyb™ Hybridization Solution (CLONTECH). Control hybridization to determine relative gel loading was accomplished using the β-tubulin probe.

Normal human tissues including spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood leukocyte, heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas and normal human fetal tissues (Human Multiple Tissue Northern Blot; CLONTECH) were all examined using the same hybridization procedure.

### **EXAMPLE 8**

#### **PCR Products Corresponding To Serine, Cysteine And Metallo-Proteases**

Based on their unique expression in either low malignant potential tumors or carcinomas, PCR-amplified cDNA products were

cloned and sequenced and the appropriate gene identified based upon nucleotide and amino acid sequences stored in the GCG and EST databases. Figures 3, 4 & 5 show the PCR product displays comparing normal and carcinomatous tissues using redundant primers for serine proteases (Figure 3), for cysteine proteases (Figure 4) and for metallo-proteases (Figure 5). Note the differential expression in the carcinoma tissues versus the normal tissues. The proteases were identified using redundant cDNA primers (see Table 2) directed towards conserved sequences that are associated with intrinsic enzyme activity (for serine proteases, cysteine proteases and metallo-proteases) by comparing mRNA expression in normal, low malignant potential and overt ovarian carcinoma tissues according to Sakanari *et al.* [*Biochemistry* 86, 4863-4867 (1989)].

15

## **EXAMPLE 9**

### **Serine Proteases**

For the serine protease group, using the histidine domain primer sense, S1, in combination with antisense primer AS2, the



following proteases were identified:

(a) Hepsin, a trypsin-like serine protease cloned from hepatoma cells shown to be a cell surface protease essential for the growth of hepatoma cells in culture and highly expressed in hepatoma tumor cells (Figure 3, Lane 4);

(b) Complement factor B protease (human factor IX), a protease involved in the coagulation cascade and associated with the production and accumulation of fibrin split products associated with tumor cells (Figure 3, Lane 4). Complement factor B belongs in the family of coagulation factors X (Christmas factor). As part of the intrinsic pathway, complement factor B catalyzes the proteolytic activation of coagulation factor X in the presence of  $\text{Ca}^{2+}$  phospholipid and factor VIIIa e5; and

(c) A stratum corneum chymotryptic enzyme (SCCE) serine protease involved in desquamation of skin cells from the human stratum corneum (Figure 3, Lane 4). SCCE is expressed in keratinocytes of the epidermis and functions to degrade the cohesive structures in the cornified layer to allow continuous skin surface shedding.

## **EXAMPLE 10**

### **Cysteine Proteases**

In the cysteine protease group, using redundant sense  
5 and anti-sense primers for cysteine proteases, one unique PCR  
product was identified by overexpression in ovarian carcinoma when  
compared to normal ovarian tissue (Figure 4, Lanes 3-5). Cloning  
and sequencing this PCR product identified a sequence of Cathepsin  
L, which is a lysosomal cysteine protease whose expression and  
10 secretion is induced by malignant transformation, growth factors and  
tumor promoters. Many human tumors (including ovarian) express  
high levels of Cathepsin L. Cathepsin L cysteine protease belongs in  
the stromolysin family and has potent elastase and collagenase  
activities. Published data indicates increased levels in the serum of  
15 patients with mucinous cystadenocarcinoma of the ovary. It has not  
heretofore been shown to be expressed in other ovarian tumors.

## **EXAMPLE 11**

### **Metallo-Proteases**

Using redundant sense and anti-sense primers for the  
5 metallo-protease group, one unique PCR product was detected in the  
tumor tissue which was absent in normal ovarian tissue (Figure 5,  
Lanes 2-5). Subcloning and sequencing this product indicates it has  
complete homology in the appropriate region with the so-called  
PUMP-1 (MMP-7) gene. This zinc-binding metallo-protease is  
10 expressed as a proenzyme with a signal sequence and is active in  
gelatin and collagenase digestion. PUMP-1 has also been shown to be  
induced and overexpressed in 9 of 10 colorectal carcinomas  
compared to normal colon tissue, suggesting a role for this substrate  
in the progression of this disease.

15

## **EXAMPLE 12**

### **Expression Of Hepsin**

The expression of the serine protease hepsin gene in 8  
20 normal, 11 low malignant potential tumors, and 14 carcinoma (both

mucinous and serous type) by quantitative PCR using hepsin-specific primers (see Table 2) was determined (primers directed toward the  $\beta$ -tubulin message were used as an internal standard) (Table 5).

These data confirm the overexpression of the hepsin surface

5 protease gene in ovarian carcinoma, including both low malignant potential tumors and overt carcinoma. Expression of hepsin is

increased over normal levels in low malignant potential tumors, and

high stage tumors (Stage III) of this group have higher expression of hepsin when compared to low stage tumors (Stage 1) (Table 6). In

10 overt carcinoma, serous tumors exhibit the highest levels of hepsin expression, while mucinous tumors express levels of hepsin

comparable with the high stage low malignant potential group

(Figures 6 & 7).

0919048-073001

**TABLE 5****Patient Characteristics and Expression of Hepsin Gene**

|    | <u>Case</u> | <u>Histological type<sup>a</sup></u> | <u>Stage/Grade</u> | <u>LN<sup>b</sup></u> | mRNA<br>expression of<br><u>hepsin<sup>c</sup></u> |
|----|-------------|--------------------------------------|--------------------|-----------------------|--|
| 5  | 1           | normal ovary                         |                    |                       | n  |
|    | 2           | normal ovary                         |                    |                       | n  |
|    | 3           | normal ovary                         |                    |                       | n  |
|    | 4           | normal ovary                         |                    |                       | n  |
| 10 | 5           | normal ovary                         |                    |                       | n  |
|    | 6           | normal ovary                         |                    |                       | n  |
|    | 7           | normal ovary                         |                    |                       | n  |
|    | 8           | normal ovary                         |                    |                       | n  |
|    | 9           | normal ovary                         |                    |                       | n  |
| 15 | 10          | normal ovary                         |                    |                       | n  |
|    | 11          | S adenoma (LMP)                      | 1 / 1              | N                     | 4+   |
|    | 12          | S adenoma (LMP)                      | 1 / 1              | NE                    | 4+   |
|    | 13          | S adenoma (LMP)                      | 1 / 1              | NE                    | n  |
|    | 14          | S adenoma (LMP)                      | 1 / 1              | N                     | 2+   |
| 20 | 15          | S adenoma (LMP)                      | 3 / 1              | P                     | 4+   |
|    | 16          | S adenoma (LMP)                      | 3 / 1              | P                     | 4+   |
|    | 17          | S adenoma (LMP)                      | 3 / 1              | P                     | 4+   |
|    | 18          | M adenoma (LMP)                      | 1 / 1              | NE                    | 4+   |
|    | 19          | M adenoma (LMP)                      | 1 / 1              | N                     | n  |
| 25 | 20          | M adenoma (LMP)                      | 1 / 1              | N                     | n  |
|    | 21          | M adenoma (LMP)                      | 1 / 1              | N                     | n  |
|    | 22          | M adenoma (LMP)                      | 1 / 1              | NE                    | n  |
|    | 23          | S carcinoma                          | 1 / 2              | N                     | 4+   |
|    | 24          | S carcinoma                          | 1 / 3              | N                     | 4+   |
| 30 | 25          | S carcinoma                          | 3 / 1              | NE                    | 2+   |
|    | 26          | S carcinoma                          | 3 / 2              | NE                    | 4+   |
|    | 27          | S carcinoma                          | 3 / 2              | P                     | 4+   |
|    | 28          | S carcinoma                          | 3 / 2              | NE                    | 2+   |
|    | 29          | S carcinoma                          | 3 / 3              | NE                    | 2+   |
| 35 | 30          | S carcinoma                          | 3 / 3              | NE                    | 4+   |
|    | 31          | S carcinoma                          | 3 / 3              | NE                    | 4+   |
|    | 32          | S carcinoma                          | 3 / 3              | NE                    | 4+   |

|    |    |             |       |    |    |
|----|----|-------------|-------|----|----|
| 5  | 33 | S carcinoma | 3 / 3 | N  | 4+ |
|    | 34 | S carcinoma | 3 / 3 | NE | n  |
|    | 35 | S carcinoma | 3 / 3 | NE | 4+ |
|    | 36 | S carcinoma | 3 / 3 | NE | 4+ |
|    | 37 | S carcinoma | 3 / 3 | NE | 4+ |
| 10 | 38 | S carcinoma | 3 / 3 | N  | 4+ |
|    | 39 | S carcinoma | 3 / 2 | NE | 2+ |
|    | 40 | S carcinoma | 3 / 3 | NE | 4+ |
|    | 41 | S carcinoma | 3 / 2 | NE | 4+ |
|    | 42 | M carcinoma | 1 / 2 | N  | n  |
| 15 | 43 | M carcinoma | 2 / 2 | NE | 4+ |
|    | 44 | M carcinoma | 2 / 2 | N  | 4+ |
|    | 45 | M carcinoma | 3 / 1 | NE | n  |
|    | 46 | M carcinoma | 3 / 2 | NE | 4+ |
|    | 47 | M carcinoma | 3 / 2 | NE | n  |
| 20 | 48 | M carcinoma | 3 / 3 | NE | n  |
|    | 49 | E carcinoma | 2 / 3 | N  | 4+ |
|    | 50 | E carcinoma | 3 / 2 | NE | 4+ |
|    | 51 | E carcinoma | 3 / 3 | NE | 4+ |
|    | 52 | C carcinoma | 1 / 3 | N  | 4+ |
| 25 | 53 | C carcinoma | 1 / 1 | N  | 4+ |
|    | 54 | C carcinoma | 3 / 2 | P  | 4+ |

<sup>a</sup>S, serous; M, mucinous; E, endometrioid; C, clear cell; <sup>b</sup>LN, lymph node metastasis; P, positive; N, negative; NE, not examined; <sup>c</sup>n, normal range = mean  $\pm$ 2SD; 2+, mean  $\pm$ 2SD to  $\pm$ 4SD; 4+, mean  $\pm$ 4SD or greater.

**TABLE 6**

Overexpression of hepsin in normal ovaries and ovarian tumors

| 5  | <u>Type</u>   | <u>N</u> | Hepsin                | Ratio of<br>Hepsin<br>to $\beta$ -tubulin |
|----|---------------|----------|-----------------------|---|
|    |               |          | <u>Overexpression</u> | <u>to <math>\beta</math>-tubulin</u>      |
|    | Normal        | 10       | 0 (0%)                | 0.06 $\pm$ 0.05                           |
|    | LMP           | 12       | 7 (58.3%)             | 0.26 $\pm$ 0.19                           |
|    | Serous        | 7        | 6 (85.7%)             | 0.34 $\pm$ 0.20                           |
| 10 | Mucinous      | 5        | 1 (20.0%)             | 0.14 $\pm$ 0.12                           |
|    | Carcinomatous | 32       | 27 (84.4%)            | 0.46 $\pm$ 0.29                           |
|    | Serous        | 19       | 18 (94.7%)            | 0.56 $\pm$ 0.32                           |
|    | Mucinous      | 7        | 3 (42.9%)             | 0.26 $\pm$ 0.22                           |
|    | Endometrioid  | 3        | 3 (100%)              | 0.34 $\pm$ 0.01                           |
| 15 | Clear Cell    | 3        | 3 (100%)              | 0.45 $\pm$ 0.08                           |

### **EXAMPLE 13**

#### **Expression of SCCE and PUMP-1**

Studies using both SCCE-specific primers (Figure 8) and  
5 PUMP-specific primers (Figure 9) indicate overexpression of these  
proteases in ovarian carcinomas.

### **EXAMPLE 14**

#### **Summary Of Proteases Detected Herein**

Most of the proteases described herein were identified  
from the sense-His/antisense-Ser primer pair, yielding a 500 bp PCR  
product (Figure 1, Lane 4). Some of the enzymes are familiar, a short  
15 summary of each follows.

#### **Hepsin**

Hepsin is a trypsin-like serine protease cloned from  
hepatoma cells. Hepsin is an extracellular protease (the enzyme  
includes a secretion signal sequence) which is anchored in the  
20 plasma membrane by its amino terminal domain, thereby exposing



its catalytic domain to the extracellular matrix. Hepsin has also been shown to be expressed in breast cancer cell lines and peripheral nerve cells. Hepsin has never before been associated with ovarian carcinoma. Specific primers for the hepsin gene were synthesized and the expression of hepsin examined using Northern blots of fetal tissue and ovarian tissue (both normal and ovarian carcinoma).

Figure 10A shows that hepsin was expressed in ovarian carcinomas of different histologic types, but not in normal ovary.

Figure 10B shows that hepsin was expressed in fetal liver and fetal kidney as anticipated, but at very low levels or not at all in fetal brain and lung. Figure 10C shows that hepsin overexpression is not observed in normal adult tissue. Slight expression above the background level is observed in the adult prostate. The mRNA identified in both Northern blots was the appropriate size for the hepsin transcript. The expression of hepsin was examined in 10 normal ovaries and 44 ovarian tumors using specific primers to  $\beta$ -tubulin and hepsin in a quantitative PCR assay, and found it to be linear over 35 cycles. Expression is presented as the ratio of  $^{32}\text{P}$ -hepsin band to the internal control, the  $^{32}\text{P}$ - $\beta$ -tubulin band.

Hepsin expression was investigated in normal (N), mucinous (M) and serous (S) low malignant potential (LMP) tumors and carcinomas (CA). Figure 11A shows quantitative PCR of hepsin and internal control  $\beta$ -tubulin. Figure 11B shows the ratio of hepsin: $\beta$ -tubulin expression in normal ovary, LMP tumor, and ovarian carcinoma. It was observed that Hepsin mRNA expression levels were significantly elevated in LMP tumors, ( $p < 0.005$ ) and carcinomas ( $p < 0.0001$ ) compared to levels in normal ovary. All 10 cases of normal ovaries showed a relatively low level of hepsin mRNA expression.

Hepsin mRNA is highly overexpressed in most histopathologic types of ovarian carcinomas including some low malignant potential tumors (see Figures 11A & 11B). Most noticeably, hepsin is highly expressed in serous, endometrioid and clear cell tumors tested. It is highly expressed in some mucinous tumors, but it is not overexpressed in the majority of such tumors.

#### Stratum corneum chymotrypsin enzyme (SCCE)

The PCR product identified was the catalytic domain of

the sense-His/antisense-Ser of the stratum corneum chymotrypsin enzyme. This extracellular protease was cloned, sequenced and shown to be expressed on the surface of keratinocytes in the epidermis. Stratum corneum chymotrypsin enzyme is a

5 chymotrypsin-like serine protease whose function is suggested to be in the catalytic degradation of intercellular cohesive structures in the stratum corneum layer of the skin. This degradation allows continuous shedding (desquamation) of cells from the skin surface. The subcellular localization of stratum corneum chymotrypsin

10 enzyme is in the upper granular layer in the stratum corneum of normal non-palmoplantar skin and in the cohesive parts of hypertrophic plantar stratum corneum. Stratum corneum chymotrypsin enzyme is exclusively associated with the stratum corneum and has not so far been shown to be expressed in any

15 carcinomatous tissues.

Northern blots were probed with the PCR product to determine expression of stratum corneum chymotrypsin enzyme in fetal tissue and ovarian carcinoma (Figures 12A & 12B). Noticeably, detection of stratum corneum chymotrypsin enzyme messenger RNA

20 on the fetal Northern was almost non-existent (a problem with the

probe or the blot was excluded by performing the proper controls). A faint band appeared in fetal kidney. On the other hand, stratum corneum chymotrypsin enzyme mRNA is abundant in the ovarian carcinoma mRNA (Figure 12B). Two transcripts of the correct size  
5 are observed for stratum corneum chymotrypsin enzyme. The same panel of cDNA used for hepsin analysis was used for stratum corneum chymotrypsin enzyme expression.

No stratum corneum chymotrypsin enzyme expression was detected in the normal ovary lane of the Northern blot. A  
10 comparison of all candidate genes, including a loading marker ( $\beta$ -tubulin), was shown to confirm that this observation was not a result of a loading bias. Quantitative PCR using stratum corneum chymotrypsin enzyme primers, along with  $\beta$ -tubulin internal control primers, confirmed the overexpression of stratum corneum  
15 chymotrypsin enzyme mRNA in carcinoma of the ovary with no expression in normal ovarian tissue (Figure 13).

Figure 13A shows a comparison using quantitative PCR of stratum corneum chymotrypsin enzyme cDNA from normal ovary and ovarian carcinomas. Figure 13B shows the ratio of stratum

corneum chymotrypsin enzyme to the  $\beta$ -tubulin internal standard in 10 normal and 44 ovarian carcinoma tissues. Again, it is observed that stratum corneum chymotrypsin enzyme is highly overexpressed in ovarian carcinoma cells. It is also noted that some mucinous tumors overexpress stratum corneum chymotrypsin enzyme, but the majority do not.

#### Protease M

Protease M was identified from subclones of the His--ser primer pair. This protease was first cloned by Anisowicz, *et al.*, [Molecular Medicine, 2, 624-636 (1996)] and shown to be overexpressed in carcinomas. A preliminary evaluation indicates that this enzyme is overexpressed in ovarian carcinoma (Figure 14).

#### Cofactor I and Complement factor B

Several serine proteases associated with the coagulation pathway were also subcloned. Examination of normal and ovarian carcinomas by quantitative PCR for expression of these enzymes, it was noticeable that this mRNA was not clearly overexpressed in ovarian carcinomas when compared to normal ovarian tissue. It

should be noted that the same panel of tumors was used for the evaluation of each candidate protease.

5

### **EXAMPLE 15**

#### **Summary Of Previously Unknown Proteases Detected Herein**

##### **TADG-12**

TADG-12 was identified from the primer pairs, sense-  
10 His/antisense-Asp (see Figure 1, Lanes 1 & 2). Upon subcloning both  
PCR products in lane 2, the 200 bp product had a unique protease-  
like sequence not included in GenBank. This 200 bp product contains  
many of the conserved amino acids common for the His-Asp domain  
of the family of serine proteins. The second and larger PCR product  
15 (300 bp) was shown to have a high degree of homology with TADG-  
12 (His-Asp sequence), but also contained approximately 100 bp of  
unique sequence. Synthesis of specific primers and the sequencing  
of the subsequent PCR products from three different tumors  
demonstrated that the larger PCR product (present in about 50% of  
20 ovarian carcinomas) includes an insert of about 100 bp near the 5'

end (and near the histidine) of the sequence. This insert may be a retained genomic intron because of the appropriate position of splice sites and the fact that the insert does not contain an open reading frame (see Figure 15). This suggests the possibility of a splice site mutation which gives rise to retention of the intron, or a translocation of a sequence into the TADG-12 gene in as many as half of all ovarian carcinomas.

#### TADG-13 and TADG-14

Specific primers were synthesized for TADG-13 and TADG-14 to evaluate expression of genes in normal and ovarian carcinoma tissue. Northern blot analysis of ovarian tissues indicates the transcript for the TADG-14 gene is approximately 1.4 kb and is expressed in ovarian carcinoma tissues (Figure 16A) with no noticeable transcript presence in normal tissue. In quantitative PCR studies using specific primers, increased expression of TADG-14 in ovarian carcinoma tissues was noted compared to a normal ovary (Figure 16B). The presence of a specific PCR product for TADG-14 in both an HeLa library and an ovarian carcinoma library was also confirmed. Several candidate sequences corresponding to TADG-14

have been screened and isolated from the HeLa library.

Clearly from sequence homology, these genes fit into the family of serine proteases. TADG-13 and -14 are, however, heretofore undocumented genes which the specific primers of the invention allow to be evaluated in normal and tumor cells, and with which the presence or absence of expression of these genes is useful in the diagnosis or treatment selection for specific tumor types.

### PUMP-1

In a similar strategy using redundant primers to metal binding domains and conserved histidine domains, a differentially expressed PCR product identical to matrix metallo-protease 7 (MMP-7) was identified, herein called PUMP-1. Using specific primers for PUMP-1, PCR produced a 250 bp product for Northern blot analysis.

PUMP-1 is differentially expressed in fetal lung and kidney tissues. Figure 17A shows the expression of PUMP-1 in human fetal tissue, while no transcript could be detected in either fetal brain or fetal liver. Figure 17B compares PUMP-1 expression in normal ovary and carcinoma subtypes using Northern blot analysis. Notably, PUMP-1 is expressed in ovarian carcinoma tissues, and



again, the presence of a transcript in normal tissue was not detected. Quantitative PCR comparing normal versus ovarian carcinoma expression of the PUMP-1 mRNA indicates that this gene is highly expressed in serous carcinomas, including most low malignant serous tumors, and is, again, expressed to a lesser extent in mucinous tumors (see Figures 18A & 18B). PUMP-1, however, is so far the protease most frequently found overexpressed in mucinous tumors (See Table 7).

#### Cathepsin-L

Using redundant cysteine protease primers to conserved domains surrounding individual cysteine and histidine residues, the cathepsin-L protease was identified in several serous carcinomas. An initial examination of the expression of cathepsin L in normal and ovarian tumor tissue indicates that transcripts for the cathepsin-L protease are present in both normal and tumor tissues (Figure 19). However, its presence or absence in combination with other proteases of the present invention permits identification of specific tumor types and treatment choices.

## Discussion

Redundant primers to conserved domains of serine, metallo-, and cysteine proteases have yielded a set of genes whose mRNAs are overexpressed in ovarian carcinoma. The genes which are

5 clearly overexpressed include the serine proteases hepsin, stratum corneum chymotrypsin enzyme, protease M TADG12, TADG14 and the metallo-protease PUMP-1 (see Figure 19 and Table 7). Northern blot analysis of normal and ovarian carcinoma tissues, summarized in Figure 14, indicated overexpression of hepsin, stratum corneum

10 chymotrypsin enzyme, PUMP-1 and TADG-14. A  $\beta$ -tubulin probe to control for loading levels was included.

091904-073001  
T00E20-B406T660

**TABLE 7****Overexpression of Proteases in Ovarian Tumors**

|    | <b>Type</b> | <b>N</b> | <b>Hepsin</b> | <b>SCCE</b>   | <b>Pump-1</b> | <b>Protease M</b> |
|----|-------------|----------|---------------|---------------|---------------|-------------------|
| 5  | Normal      | 10       | 0% (0/10)     | 0% (0/10)     | 0% (0/10)     | 0% (0/10)         |
|    | LMP         | 12       | 58.3% (7/12)  | 66.7% (8/12)  | 75.0% (9/12)  | 75% (9/12)        |
|    | serous      | 7        | 85.7% (6/7)   | 85.7% (6/7)   | 85.7% (6/7)   | 100% (7/7)        |
|    | mucinous    | 5        | 20.0% (1/5)   | 40.0% (2/5)   | 60% (3/5)     | 40.0% (2/5)       |
|    | Carcinoma   | 32       | 84.4% (27/32) | 78.1% (25/32) | 81.3% (26/32) | 90.6% (29/32)     |
| 10 | serous      | 19       | 94.7% (18/19) | 89.5% (17/19) | 78.9% (15/19) | 94.7% (18/19)     |
|    | mucinous    | 7        | 42.9% (3/7)   | 28.6% (2/7)   | 71.4% (5/7)   | 85.7% (6/7)       |
|    | endometr.   | 3        | 100% (3/3)    | 100% (3/3)    | 100% (3/3)    | 100% (3/3)        |
|    | clear cell  | 3        | 100% (3/3)    | 100% (3/3)    | 100% (3/3)    | 67.7% (2/3)       |

For the most part, these proteins previously have not been associated with the extracellular matrix of ovarian carcinoma cells. No panel of proteases which might contribute to the growth, shedding, invasion and colony development of metastatic carcinoma has been previously described, including the three new candidate serine proteases which are herein disclosed. The establishment of an extracellular protease panel associated with either malignant growth or malignant potential offers the opportunity for the identification of

diagnostic or prognostic markers and for therapeutic intervention through inhibition or down regulation of these proteases.

The availability of the instant gene-specific primers coding for the appropriate region of tumor specific proteases allows for the amplification of a specific cDNA probe using Northern and Southern analysis, and their use as markers to detect the presence of the cancer in tissue. The probes also allow more extensive evaluation of the expression of the gene in normal ovary versus low malignant potential tumor, as well as both high- and low-stage carcinomas. The evaluation of a panel of fresh frozen tissue from all the carcinoma subtypes (Table 4) allowed the determination of whether a protease is expressed predominantly in early stage disease or within specific carcinoma subtypes. It was also determined whether each gene's expression is confined to a particular stage in tumor progression and/or is associated with metastatic lesions. Detection of specific combinations of proteases is an identifying characteristic of the specific tumor types and yields valuable information for diagnoses and treatment selection. Particular tumor types may be more accurately diagnosed by the characteristic expression pattern of each specific tumor.

## **EXAMPLE 16**

5

### **Hepsin Peptide Ranking**

For vaccine or immune stimulation, individual 9-mers to 11-mers of the hepsin protein were examined to rank the binding of individual peptides to the top 8 haplotypes in the general population (Parker et al., (1994)). The computer program used for this analyses can be found on the web site of National Institutes of Health. Table 8 shows the peptide ranking based upon the predicted half-life of each peptide's binding to a particular HLA allele. A larger half-life indicates a stronger association with that peptide and the particular HLA molecule. The hepsin peptides that strongly bind to an HLA allele are putative immunogens, and are used to inoculate an individual against hepsin.

**TABLE 8**  
**Hepsin peptide ranking**

|    | HLA Type<br>& Ranking | Start | Peptide                              | Predicted<br>Dissociation <sub>1/2</sub> | SEQ<br>ID No. |
|----|-----------------------|-------|--------------------------------------|--|---------------|
|    | HLA A0201             |       |                                      |  |               |
|    | 1                     | 170   | <sup>1 2 3 4 5 6 7 8</sup> SLGRWPWQV | 521.640                                  | 28            |
|    | 2                     | 191   | SLLSGDWVL                            | 243.051                                  | 29            |
|    | 3                     | 229   | GLQLGVQAV                            | 159.970                                  | 30            |
| 5  | 4                     | 392   | KVSDFREWI                            | 134.154                                  | 31            |
|    | 5                     | 308   | VLQEARVPI                            | 72.717                                   | 32            |
|    | 6                     | 130   | RLLEVISVC                            | 71.069                                   | 33            |
|    | 7                     | 98    | ALTHSELDV                            | 69.552                                   | 34            |
|    | 8                     | 211   | VLSRWRVFA                            | 46.451                                   | 35            |
| 10 | 9                     | 26    | LLLLTAIGA                            | 31.249                                   | 36            |
|    | 10                    | 284   | ALVDGKICT                            | 30.553                                   | 37            |
|    | 11                    | 145   | FLAAICQDC                            | 22.853                                   | 38            |
|    | 12                    | 192   | LSSGDWVLT                            | 21.536                                   | 39            |
|    | 13                    | 20    | ALTAGTLLL                            | 21.362                                   | 40            |
|    | 14                    | 259   | ALVHLSSPL                            | 21.362                                   | 41            |
|    | 15                    | 277   | CLPAAGQAL                            | 21.362                                   | 42            |
|    | 16                    | 230   | LQLGVQAVV                            | 18.186                                   | 43            |
|    | 17                    | 268   | PLTEYIQPV                            | 14.429                                   | 44            |
|    | 18                    | 31    | AIGAASWAI                            | 10.759                                   | 45            |
|    | 19                    | 285   | LVDGKICTV                            | 9.518                                    | 46            |
| 20 | 20                    | 27    | LLLTAIGAA                            | 9.343                                    | 47            |
|    | HLA A0205             |       |                                      |  |               |
|    | 1                     | 191   | SLLSGDWVL                            | 25.200                                   | 48            |
|    | 2                     | 163   | IVGGRDTSI                            | 23.800                                   | 49            |
|    | 3                     | 392   | KVSDFREWI                            | 18.000                                   | 50            |
|    | 4                     | 64    | MVFDKTEGT                            | 15.300                                   | 51            |
|    | 5                     | 236   | AVVYHGGYL                            | 14.000                                   | 52            |
|    | 6                     | 55    | QVSSADARL                            | 14.000                                   | 53            |
|    | 7                     | 130   | RLLEVISVC                            | 9.000                                    | 54            |
|    | 8                     | 230   | LQLGVQAVV                            | 8.160                                    | 55            |
| 30 | 9                     | 20    | ALTAGTLLL                            | 7.000                                    | 56            |
|    | 10                    | 259   | ALVHLSSPL                            | 7.000                                    | 57            |
|    | 11                    | 277   | CLPAAGQAL                            | 7.000                                    | 58            |
|    | 12                    | 17    | KVAALTAGT                            | 6.000                                    | 59            |

09019048-073001

|         |    |     |                  |         |    |
|---------|----|-----|------------------|---------|----|
| 5       | 13 | 285 | LVDGKICTV        | 5.440   | 60 |
|         | 14 | 308 | VLQEARVPI        | 5.100   | 61 |
|         | 15 | 27  | LLLTAIGAA        | 5.100   | 62 |
|         | 16 | 229 | GLQLGVQAV        | 4.000   | 63 |
|         | 17 | 313 | RVPIISNDV        | 4.000   | 64 |
|         | 18 | 88  | LSCEEMGFL        | 3.570   | 65 |
|         | 19 | 192 | LLSGDWVLT        | 3.400   | 66 |
|         | 20 | 284 | ALVDGKICT        | 3.000   | 67 |
| HLA A1  |    |     |                  |         |    |
| 10      | 1  | 89  | SCEEMGFLR        | 45.000  | 68 |
|         | 2  | 58  | SADARLMVF        | 25.000  | 69 |
|         | 3  | 393 | VSDFREWIF        | 7.500   | 70 |
|         | 4  | 407 | HSEASGMVT        | 6.750   | 71 |
|         | 5  | 137 | VCDCPRGRF5.00072 |         |    |
| 15      | 6  | 269 | LTEYIQPVC        | 4.500   | 73 |
|         | 7  | 47  | DQEPLYPVQ        | 2.700   | 74 |
|         | 8  | 119 | CVDEGRLPH        | 2.500   | 75 |
|         | 9  | 68  | KTEGTWRL         | 2.250   | 76 |
|         | 10 | 101 | HSELDVRTA        | 1.350   | 77 |
| 20      | 11 | 250 | NSEENSNDI        | 1.350   | 78 |
|         | 12 | 293 | VTGWGNTQY        | 1.250   | 79 |
|         | 13 | 231 | QLGVQAVVY        | 1.000   | 80 |
|         | 14 | 103 | ELDVRTAGA        | 1.000   | 81 |
|         | 15 | 378 | GTGCALAK         | 1.000   | 82 |
| 25      | 16 | 358 | VCEDSISRT        | 0.900   | 83 |
|         | 17 | 264 | SSPLPLTEY        | 0.750   | 84 |
|         | 18 | 87  | GLSCEEMGF        | 0.500   | 85 |
|         | 19 | 272 | YIQPVCLPA        | 0.500   | 86 |
|         | 20 | 345 | GIDACQGDS        | 0.500   | 87 |
| HLA A24 |    |     |                  |         |    |
| 30      | 1  | 301 | YYGQQAGVL        | 200.000 | 88 |
|         | 2  | 238 | VYHGGYLPF        | 100.000 | 89 |
|         | 3  | 204 | CFPERNRVL        | 36.000  | 90 |
|         | 4  | 117 | FFCVDEGRL        | 20.000  | 91 |
| 35      | 5  | 124 | RLPHTQRLL        | 12.000  | 92 |
|         | 6  | 80  | RSNARVAGL        | 12.000  | 93 |
|         | 7  | 68  | KTEGTWRL         | 12.000  | 94 |
|         | 8  | 340 | GYPEGGIDA        | 9.000   | 95 |
|         | 9  | 242 | GYPFRDPN         | 9.000   | 96 |

|        |    |     |           |        |     |
|--------|----|-----|-----------|--------|-----|
| 5      | 10 | 51  | LYPVQVSSA | 7.500  | 97  |
|        | 11 | 259 | ALVHLSSPL | 7.200  | 98  |
|        | 12 | 277 | CLPAAGQAL | 7.200  | 99  |
|        | 13 | 191 | SLLSGDWVL | 6.000  | 100 |
|        | 14 | 210 | RVLSRWRF  | 6.000  | 101 |
|        | 15 | 222 | VAQASPHGL | 6.000  | 102 |
|        | 16 | 236 | AVVYHGGYL | 6.000  | 103 |
|        | 17 | 19  | AALTAGTLL | 6.000  | 104 |
|        | 18 | 36  | SWAIVAVLL | 5.600  | 105 |
|        | 19 | 35  | ASWAIVAVL | 5.600  | 106 |
| 10     | 20 | 300 | QYYGQQAGV | 5.600  | 107 |
| HLA B7 |    |     |           |        |     |
| 15     | 1  | 363 | ISRTPRWRL | 90.000 | 108 |
|        | 2  | 366 | TPRWRLCGI | 80.000 | 109 |
|        | 3  | 236 | AVVYHGGYL | 60.000 | 110 |
|        | 4  | 13  | CSRPKVAAL | 40.000 | 111 |
|        | 5  | 179 | SLRYDGAHL | 40.000 | 112 |
|        | 6  | 43  | LLRSDQEPL | 40.000 | 113 |
|        | 7  | 19  | AALTAGTLL | 36.000 | 114 |
|        | 8  | 55  | QVSSADARL | 20.000 | 115 |
|        | 9  | 163 | IVGGRDTS� | 20.000 | 116 |
|        | 10 | 140 | CPRGRFLAA | 20.000 | 117 |
| 20     | 11 | 20  | ALTAGTLLL | 12.000 | 118 |
|        | 12 | 409 | EASGMVTQL | 12.000 | 119 |
|        | 13 | 259 | ALVHLSSPL | 12.000 | 120 |
|        | 14 | 35  | ASWAIVAVL | 12.000 | 121 |
|        | 15 | 184 | GAHLCCGSL | 12.000 | 122 |
|        | 16 | 18  | VAALTAGTL | 12.000 | 123 |
|        | 17 | 222 | VAQASPHGL | 12.000 | 124 |
|        | 18 | 224 | QASPHGLQL | 12.000 | 125 |
|        | 19 | 265 | SPLPLTEYI | 8.000  | 126 |
|        | 20 | 355 | GPFVCEDSI | 8.00   | 127 |
| HLA B8 |    |     |           |        |     |
| 35     | 1  | 13  | CSRPKVAAL | 80.000 | 128 |
|        | 2  | 366 | TPRWRLCGI | 80.000 | 129 |
|        | 3  | 140 | CPRGRFLAA | 16.000 | 130 |
|        | 4  | 152 | DCGRRKLPV | 4.800  | 131 |
|        | 5  | 363 | ISRTPRWRL | 4.000  | 132 |
|        | 6  | 163 | IVGGRDTS� | 4.000  | 133 |



|    |           |     |             |         |     |
|----|-----------|-----|-------------|---------|-----|
|    | 7         | 331 | QIKPKMFCA   | 4.000   | 134 |
|    | 8         | 80  | RSNARVAGL   | 2.000   | 135 |
|    | 9         | 179 | SLRYDGAHL   | 1.600   | 136 |
|    | 10        | 43  | LLRSDQEPL   | 1.600   | 137 |
| 5  | 11        | 409 | EASGMVTQL   | 1.600   | 138 |
|    | 12        | 311 | EARVPIISN   | 0.800   | 139 |
|    | 13        | 222 | VAQASPHGL   | 0.800   | 140 |
|    | 14        | 19  | AALTAGTLL   | 0.800   | 141 |
|    | 15        | 18  | VAALTAGTL   | 0.800   | 142 |
| 10 | 16        | 184 | GAHLCGGSL   | 0.800   | 143 |
|    | 17        | 224 | QASPHGLQL   | 0.800   | 144 |
|    | 18        | 82  | NARVAGLSC   | 0.800   | 145 |
|    | 19        | 204 | CFPERNRVL   | 0.600   | 146 |
|    | 20        | 212 | LSRWRVFAG   | 0.400   | 147 |
| 15 | HLA B2702 |     | 03456789180 |         | 148 |
|    | 1         | 172 | GRWPWQVSL   | 300.000 | 149 |
|    | 2         | 44  | LRSDQEPLY   | 200.00  | 150 |
|    | 3         | 155 | RRKLPVDRI   | 180.000 | 151 |
|    | 4         | 213 | SRWRVFAGA   | 100.000 | 152 |
| 20 | 5         | 166 | GRDTSLGRW   | 100.000 | 153 |
|    | 6         | 369 | WRLCGIVSW   | 100.000 | 154 |
|    | 7         | 180 | LRDYGALHC   | 100.000 | 155 |
|    | 8         | 96  | LRALTHSEL   | 60.000  | 156 |
|    | 9         | 396 | FREWIFQAI   | 60.000  | 157 |
| 25 | 10        | 123 | GRLPHTQRL   | 60.000  | 158 |
|    | 11        | 207 | ERNRVLSRW   | 30.000  | 159 |
|    | 12        | 209 | NRVLSRWV    | 20.000  | 160 |
|    | 13        | 14  | SRPKVAALT   | 20.000  | 161 |
|    | 14        | 106 | VRTAGANGT   | 20.000  | 162 |
| 30 | 15        | 129 | QRLLEVISV   | 20.000  | 163 |
|    | 16        | 349 | CQGDSGGPF   | 20.000  | 164 |
|    | 17        | 61  | ARLMVFDKT   | 20.000  | 165 |
|    | 18        | 215 | WRVFAGAVA   | 20.000  | 166 |
|    | 19        | 143 | GRFLAAICQ   | 10.000  | 167 |
| 35 | 20        | 246 | FRDPNSEEN   | 10.000  | 168 |
|    | HLA B4403 |     |             |         |     |
|    | 1         | 132 | LEVISVCDC   | 36.000  | 169 |
|    | 2         | 91  | EEMGFLRAL   | 18.000  | 170 |
|    | 3         | 264 | SSPLPLTEY   | 13.500  | 171 |

|    |    |     |           |        |     |
|----|----|-----|-----------|--------|-----|
| 5  | 4  | 310 | QEARVPIIS | 12.000 | 171 |
|    | 5  | 319 | NDVCNGADF | 10.000 | 172 |
|    | 6  | 4   | KEGGRTVPC | 9.000  | 173 |
|    | 7  | 251 | SEENSNDIA | 8.000  | 174 |
|    | 8  | 256 | NDIALVHLS | 7.500  | 175 |
| 10 | 9  | 294 | TGWGNTQYY | 6.750  | 176 |
|    | 10 | 361 | DSISRTPRW | 6.750  | 177 |
|    | 11 | 235 | QAVVYHGGY | 6.000  | 178 |
|    | 12 | 109 | AGANGTSGF | 6.000  | 179 |
|    | 13 | 270 | TEYIQPVCL | 6.000  | 180 |
| 15 | 14 | 174 | WPWQVSLRY | 4.500  | 181 |
|    | 15 | 293 | VTGWGNTQY | 4.500  | 182 |
|    | 16 | 69  | TEGTWRLLC | 4.000  | 183 |
|    | 17 | 90  | CEEMGFLRA | 4.000  | 184 |
|    | 18 | 252 | EENSNDIAL | 4.000  | 185 |
| 20 | 19 | 48  | QEPLYPVQV | 4.000  | 186 |
|    | 20 | 102 | SELDVRTAG | 3.600  | 187 |

### EXAMPLE 17

#### Hepsin Peptides As Target Epitopes For Human CD8<sup>+</sup> Cytotoxic T Cells

Two computer programs were used to identify 9-mer peptides containing binding motifs for HLA class I molecules. The first, based on a scheme devised by Parker et al (1994), was developed by the Bioinformatics and Molecular Analysis Section (BIMAS) of the Center for Information Technology, NIH, and the

second, known as SYFPEITHI, was formulated by Rammensee and colleagues at the University of Tübingen, Germany.

Peptides that possessed HLA A2.1 binding motifs were synthesized and tested directly for their ability to bind HLA A2.1.

5 This technique employs T2 cells which are peptide transporter-deficient and thus express low endogenous HLA class I levels due to inability to load peptide and stabilize HLA class I folding for surface expression. It has been showed that addition of exogenous peptides capable of binding HLA A2.1 (A\*0201) could increase the number of properly folded HLA A2.1 molecules on the cell surface, as revealed by flow cytometry (Nijman et al, 1993).

10 Peptides that possessed binding motifs for HLA class I molecules other than A2.1 were tested directly for their ability to induce specific CD8<sup>+</sup> CTL responses from normal adult donors as described below.

15 Monocyte-derived dendritic cells were generated from peripheral blood drawn from normal adult donors of the appropriate HLA type. Adherent monocytes were cultured in AIM-V (Gibco-BRL) supplemented with GM-CSF and IL-4 according to standard techniques (Santin et al, 2000, 2001). After 5-6 days, dendritic cell

maturation was induced by addition of PGE<sub>2</sub>, IL-1 $\beta$  and TNF $\alpha$  for a further 48 h.

Mature dendritic cells were loaded with peptide ( $2 \times 10^6$  dendritic cells with 50  $\mu$ g/ml peptide in 1 ml serum-free AIM-V medium for 2 h at 37°C) and washed once prior to culture with  $1 \times 10^6$ /ml peripheral blood mononuclear cells (PBMC) in AIM-V or AIM-V plus 5% human AB serum. The PBMC:DC ratio was between 20:1 and 30:1. After 7 days, responder T cells were restimulated with peptide-loaded, irradiated autologous dendritic cells or peripheral blood mononuclear cells at responder:stimulator ratios between 10:1 and 20:1 or 1:1 and 1:10 respectively. At this point, cultures were supplemented with recombinant human IL-2 (10-100 U/ml), and fed with 50-75% changes of fresh medium plus IL-2 every 2-4 days. T cell lines were established and maintained by peptide restimulation every 14-21 days. Responder CD8<sup>+</sup> T cells were purified by positive selection with anti-CD8-coupled magnetic beads (DynaI, Inc.) after the 2<sup>nd</sup> or 3<sup>rd</sup> antigen stimulation.

Peptide-specific cytotoxicity was tested in standard 5-6 h microwell <sup>51</sup>Cr-release assays (Nazaruk et al, 1998). Autologous

EBV-transformed lymphoblastoid cell lines (LCL) were loaded with peptide (50 µg/ml, 1 h at 37°C) and subsequently <sup>51</sup>Cr-labeled (50 µCi in 200-300 µl, 1 h at 37°C). Peptide-loaded <sup>51</sup>Cr-labeled LCL were incubated with CD8<sup>+</sup> T cells at effector-target ratio between 5:1 and 1.25:1. Cytotoxicity was recorded as percentage <sup>51</sup>Cr released into culture supernatants.

Hepsin peptide 170-178 (SEQ ID No. 28) is an HLA A2.1-binding peptide, as revealed by upregulation of A2.1 expression in T2 cells (data not shown). CD8<sup>+</sup> CTL specific for hepsin 170-178 killed peptide-loaded autologous lymphoblastoid cell lines, but did not kill control, peptide-free lymphoblastoid cell lines (Figure 20). Heterologous HLA A2.1-expressing peptide-loaded lymphoblastoid cell lines were efficiently killed, but targets lacking HLA A2.1 were not killed. Natural killer-sensitive K562 cells were not lysed. Cytotoxicity against hepsin 170-178 loaded lymphoblastoid cell lines could be blocked with a monoclonal antibody specific for a non-polymorphic HLA class I determinant, confirming that lysis was HLA class I-restricted. Cytotoxicity was also blocked by MAb specific for HLA A2.1

Hepsin peptide 172-180 (SEQ ID No. 148) was predicted by computer analysis to bind HLA B27. While this could not be demonstrated directly, cytotoxicity assays showed that CD8<sup>+</sup> CTL specific for hepsin 172-180 could kill peptide-loaded, HLA B27-expressing autologous and heterologous lymphoblastoid cell lines, but failed to recognize heterologous peptide-loaded lymphoblastoid cell lines that did not express HLA B27.

CD8<sup>+</sup> CTL specific for hepsin 172-180 killed peptide-loaded autologous lymphoblastoid cell lines, but did not kill peptide-free control lymphoblastoid cell lines (Figure 21). Natural killer-sensitive K562 cells were not lysed. Cytotoxicity against hepsin 172-180 loaded lymphoblastoid cell lines could be blocked with MAb specific for a non-polymorphic HLA class I determinant, confirming that lysis was HLA class I-restricted.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication was specifically and individually

indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

09919048-073001  
TOOELO SHOT6T660